There were 82 (71 men and 11 women) patients without NCL progression(the control group) and 110 (89 men and 21 women) patients with NCL progression (the progression groups).
There was no significant differences in age,sex,history of diabetes mellius,rates of ,hyperlipidemia, smoking, myocardial infarction, PCI, CABG, heart rate, systolic arterial pressure, left ventricular ejection fractions (LVEF), cardiac troponin I (cTnI) peak value,Triglyceride(TG),total cholesterol (TCHO),High density liptein cholesterol(HDL-C),low-density lipopro-tein cholesterol (LDL-C) ,Total three-triiodothyronine(TT3),total thyroxine(TT4),free triiodothyronine(FT3),C reactive protein (CRP),urine acid(UA), Time from attack to reperfusion,myocardial blush grade (MBG) of 0–1 in the culprit artery,Predilation rate,Thrombolic lesion rate,≥ 2 vessle lesion rate,collateral circulation rate,culprit lesion length,complex lesion rate,and degree of baseline stenosis between the two groups (all P > 0.05)(Table 1).
There were significant differences in body mass index(BMI),fasting blood glucose(FBG),glycated albumin(GA),hemoglobinA1c(HbA1c),homocysteine(Hcy),serum creatinine(Scr),and follow-up stenosis degree between the two groups (P <0.05,P<001,P<0.0001,respectively)(Table1).
For medications, patients received a similar amount of β-blockers (62% vs. 65%), calcium antagonists (30% vs. 28%), ACEI/ARB(56% vs.54% ),and statins (91% vs. 89%) in each group (all P < 0.05) (Table1).
Multivariate logistic regression analysis indicated that fasting blood glucose(FBG)( OR: 1.274, 95%CI: 1.077-1.505,p=0.005) and serum creatinine(Scr) ( OR: 1.020, 95%CI: 1.002-1.038,p=0.027) were independent predictor of the progress of NCL after primary PCI in patients with STEMI (P< 0.05)(Table2).
Partial correlation analysis showed that fasting blood glucose level was positively correlated with NCL progression (r= 0.231, P= 0.001)(Table 3).
ROC analysis for the predictors of NCL progression indicated that a FBG level ≥5.715 mmol/L may predict the NCL progression, the sensitivity was 74.4% and the specificity was 76.6% (AUC: 0.613,CI:0.532-0.693,P <0.008)(Table 4).
Table1. Baseline clinical and angiographic characterisitcs
|
The control group
(n=110)
|
The progression group (n=82)
|
P value
|
Age(y)
Male(%)
BMI(kg/m2)
Diabetes mellius(%)
FBG(mmol/L)
GA(%)
HbAlc/%
Hypertension(%)
Hyperlipidemia(%)
Current somking(%)
Prior myocardium infarction(%)
Prior PCI(%)
Prior CABG(%)
β-blockers(%)
Calcium antagonists(%)
ACEI/ARB(%)
Statins(%)
Heart rate, beats/min
Systolic arterial pressure(mmHg)
LVEF(%)
cTnI peak value(ng/ml)
TG(mmol/L)
TCHO(mmol/L)
HDL-C(mmol/L)
LDL-C(mmol/L)
Hcy((umol/L)
TT3(nmol/L)
TT4(nmol/L)
FT3(pmol/L)
CRP(mg/L)
Scr (umol/L)
UA(umol/L)
Time from attack to reperfusion (min)
MBG 0-1
Predilation rate
Thrombolic lesion rate(%)
≥ 2 vessle lesion rate(%)
Collateral circulation rate(%)
Culprit lesion length(mm)
Complex lesion rate(%)
Baseline stenosis degree(%)
Follow-up stenosis degree(%)
|
56±9
89(80.9%)
25.5±2.9
28(25.5%)
6.4±1.6
15±3
6.3±1.4
60(54.5%)
30(27.3%)
71(64.5%)
6(5.5%)
10(9.1%)
0
68(62%)
33(30%)
61(56%)
100(91%)
82±13
133±23
53±11
21.76±3.55
1.9±1.3
4.3±1.1
1.00±0.23
2.6±0.9
15±8
1.39±0.34
109±24
4.9±0.7
3.36±1.01
71±16
346±90
371±172
45(40.91%)
34(30.91%)
27(24.55%)
52(47.27%)
28(25.45%)
29.3±13.1
44(40.00%)
32.1±13.1
60.2±14.3
|
58±10
71(86.6%)
26.7±3.6
31(37.8%)
7.2±2.2
16±4
6.7±1.3
52(63.4%)
23(28.0%)
52(63.4%)
8(9.8%)
10(12.2%)
0
53(65%)
23(28%)
44(54%)
73(89%)
83±12
131±21
53±10
22.12±3.61
2.0±1.2
4.3±1.1
0.98±0.20
2.6±0.9
18±11
1.38±0.26
109±16
4.8±0.6
5.55±1.93
77±21
348±97
373±178
34(41.46%)
27(32.53%)
21(25.61%)
41(50.00%)
21(25.61%)
29.7±13.5
32(39.02%)
34.4±13.6
78.3±15.4
|
NS
NS
<0.05
NS
<0.01
<0.05
<0.05
NS
NS
NS
NS
NS
-------
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0.05
NS
NS
NS
NS
<0.05
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0.0001
|
Data are presented as n(%) or mean ±SD unless other indicated .BMI:body mass index; FBG:fasting blood glucose; GA:glycated albumin; HbA1c:hemoglobin A1c; PCI:percutaneous coronary intervention; CABG:coronary artery bypass grafting; ACEI / ARB:angiotensin-converting enzyme inhibitor/angiotensin Ⅱ receptor blocker; LVEF:left ventricular ejection; TG:Triglyceride; TCHO:total cholesterol; HDL-C:High density liptein cholesterol; LDL-C:low-density lipoprotein cholesterol;Hcy:homocysteine; Scr:serum creatinine;TT3: Total three-triiodothyronine;TT4:total thyroxine;FT3:free triiodothyronine ; CRP:C-reactive protein;Scr:creatinine; UA:urine acid; MBG:myocardial blush grade.
Table 2.Multivariate Logistic regression analysis
Factor
|
B value
|
SE value
|
OR value
|
95%CI
|
P value
|
Scr
FBG
BMI
|
0.20
0.242
0.089
|
0.009
0.085
0.049
|
1.020
1.274
1.093
|
1.002-1.03
1.077-1.50
0.992-1.203
|
0.027
0.005
0.071
|
OR:odds ratio;CI:confidence interval;Scr:serum creatinine; FBG:fasting blood glucose;BMI:body mass index.
Table 3.Partial correlation analysis between FBG and NCL progression
Factor
|
Partial correlation coefficient
|
P value
|
FBG
|
0.231
|
0.001
|
Table 4.ROC analysis for the predictors of NCL progression
the area under the ROC curve
|
SEM
|
95% CI
|
P value
|
0.613
|
0.041
|
0.532-0.693
|
0.008
|